Dose Finding Clinical Trial With SYL040012 to Evaluate the Tolerability and Effect on Intraocular Pressure in Subjects With Ocular Hypertension or Open Angle Glaucoma
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Tallin, Estonia, 10138
- East Tallin Central Hospital
-
Tallin, Estonia, 13419
- Eye Clinic Dr. Krista Turman
-
-
-
-
-
Freiburg, Germany, 79106
- Universitaetsklinikum Freiburg
-
Köln, Germany, 50937
- Uniklinik Köln
-
Mainz, Germany, 55131
- Universitaetsklinikum Mainz
-
-
-
-
-
Barcelona, Spain, 08022
- Institut Catalâ de Retina
-
Madrid, Spain, 28034
- Hospital Universitario Ramon y Cajal
-
Madrid, Spain, 28041
- Hospital Universitario 12 de Octubre
-
Madrid, Spain, 28040
- Hospital Universitario Clinico San Carlos
-
Valladolid, Spain, 47011
- Instituto de Oftalmobiología Aplicada
-
-
Navarra
-
Pamplona, Navarra, Spain, 31008
- Clinica Universidad Navarra
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects must provide signed informed consent prior to participation in any study-related procedures.
- Male and female subjects in good or fair general health as assessed by the investigator.
- ≥18 years of age.
- Previous history or newly diagnosed elevated IOP (≥21 mmHg) with or without open-angle glaucoma in both eyes.
- Normal result, or result typical for open-angle glaucoma of the following assessments in both eyes or available results in writing within the last 3 months prior to baseline period i.e. up to 4 months before Day 1, on condition that no new ocular signs or symptoms (e.g. marked deterioration of vision, eye pain) has occurred since then which would justify a repeat examination:
- Visual field 24-2 or equivalent
- Optical coherence tomography (OCT)
- Best corrected visual acuity ≥0.5 (20/40) on the Snellen chart, or ≤ 0.3 logMAR
- Schirmer test (lacrimation)
- Funduscopy
Exclusion Criteria:
- Pregnant or breastfeeding females or those with a positive pregnancy test. Females of childbearing potential who will not use a medically acceptable contraceptive method from selection and during the hole study.
- Females of childbearing potential not willing to use a medically acceptable contraceptive method from enrolment until after the follow-up visit.
- Any current disease or condition that might compromise the respiratory, cardiovascular, endocrine, neurological, haematological, renal, or gastrointestinal function.
- Previous chronic processes or with rebound characteristics that could interfere with the study according to the investigator's judgment.
- Body temperature.
- Intolerability of any components of SYL040012 or placebo.
- Unable to comply with the clinical trial requirements as judged by the investigator.
- Beta blockers or corticosteroids use (other than cutaneous or intra-articular) for the treatment of concurrent diseases, even if sporadically, or any ocular or nasal vasoconstrictor treatment in the last 15 days prior to the first investigational product administration
- Previous refractive surgery; cataract extraction in the last 6 months
- Previous surgery for glaucoma.
- Participation in a clinical trial within 2 months before the enrolment visit
- Use of any other investigational product within 60 days before the enrolment visit.
- Other drugs for the treatment of concurrent diseases are allowed. However, their dosages should be kept constant throughout the study.
- Use of contact lenses in the last 7 days prior to the first investigational product administration and wearing contact lenses throughout the trial
- History of ocular infection or inflammation within the last 3 months before the enrolment visit
- Angle-closure or pigmentary glaucoma.
- Chronic or current acute eye diseases such as scleritis, uveitis, blepharitis, conjunctivitis, or ocular Herpes simplex virus infection
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: SYL040012 eye drops dose A
Ocular topical administration of SYL040012 eye drops dose A
|
Ocular topical administration of SYL040012 for 14 consecutive days
|
|
Experimental: SYL040012 eye drops dose B
Ocular topical administration of SYL040012 eye drops dose B
|
Ocular topical administration of SYL040012 for 14 consecutive days
|
|
Experimental: SYL040012 eye drops dose C
Ocular topical administration of SYL040012 eye drops dose C
|
Ocular topical administration of SYL040012 for 14 consecutive days
|
|
Placebo Comparator: Placebo
Ocular topical administration of placebo eye drops
|
Ocular topical administration of placebo for 14 consecutive days
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Difference in AUC between IOP Curve Obtained at the Established Time Points and the Same Curve Performed at Baseline Period
Time Frame: 14 days + (4-7 days)
|
14 days + (4-7 days)
|
|
Simple Corneal and Conjunctival Evaluation
Time Frame: 15 days + (3-6 days)
|
15 days + (3-6 days)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Visual acuity, anterior segment and ocular fundus examination as measures of local tolerability.
Time Frame: 14 days + (4-7 days)
|
14 days + (4-7 days)
|
|
Physical exploration and laboratory tests as measurements of general tolerability
Time Frame: 14 days + (4-7 days)
|
14 days + (4-7 days)
|
|
Assessment of Adverse Events Appearance
Time Frame: 14 days + (4-7 days)
|
14 days + (4-7 days)
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- SYL040012_III
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.